<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960765</url>
  </required_header>
  <id_info>
    <org_study_id>CPL200907A</org_study_id>
    <nct_id>NCT00960765</nct_id>
  </id_info>
  <brief_title>Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics</brief_title>
  <official_title>Comparison Of Endotoxin Concentration And Intestinal Microbiologic Flora Before And After Roux-En-Y Gastric Bypass Or Gastric Banding Surgery In Morbidly Obese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CPL Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synergy Bariatrics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sisters of Charity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The New York State Center of Excellence in Bioinformatics &amp; Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CPL Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is designed to investigate endotoxin (a toxin present in the wall of
      certain kinds of bacteria) levels and the type of bacteria present in the intestine before
      and after Roux-en-Y gastric bypass or gastric banding surgery in patients that meet the
      classification for morbid obesity (body mass index &gt;40 kg/m2) and type 2 diabetes. It is
      known that the type of bacteria present in the intestines of normal weight and obese
      individuals are different, and it is also known that people with obesity and type 2 diabetes
      have higher levels of endotoxin. It has been shown that the bacteria change over the long run
      after Roux-en-Y gastric bypass surgery, but the short-term effects are not known and the
      endotoxin levels after this procedure have never been studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence exists that (i) morbidly obese, T2D patients undergoing RYGB are highly likely to
      resolve T2D symptoms or dramatically reduce oral and/or insulin requirements, (ii) metabolic
      endotoxemia may incite the pathologic conditions of low-grade inflammation and subsequently
      insulin resistance, obesity and T2D, (iii) significant intestinal microbiologic flora
      differences exist between normal weight and obese/diabetic individuals, and (iv) RYGB alters
      long-term intestinal microbiologic flora. Therefore, it is logical to evaluate short- and
      long-term circulating endotoxin concentrations and intestinal microbiologic flora in context
      with weight loss and restoration of euglycemia to expand our knowledge of the mechanism of
      the benefits observed following RYGB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Gastric Bypass</condition>
  <arm_group>
    <arm_group_label>Roux-En-Y Gastric Bypass</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Banding</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sucessful Response to RYGB</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Failed Response to RYGB</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, urine, stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Morbidly obese (BMI &gt; 40 kg/m2) patients with T2D
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years of age

          -  Morbid obesity (BMI &gt; 40 kg/m2)

          -  Confirmed T2D diagnosis/date of onset

        Exclusion Criteria:

          -  Age &lt; 18 years of age

          -  BMI &lt; 40 kg/m2

          -  Type 1 diabetes

          -  Chronic use of non-steroidal anti-inflammatory agents (NSAIDs)

          -  Chronic use of systemic corticosteroids

          -  Anticipated inability to maintain current statin, angiotensin converting enzyme
             inhibitor (ACEI), or angiotensin receptor blocking agent (ARB) regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Caruana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Bariatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sisters of Charity Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Bariatrics</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CPL Associates</investigator_affiliation>
    <investigator_full_name>Scott Monte</investigator_full_name>
    <investigator_title>Program Director</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Gastric Bypass</keyword>
  <keyword>Gastric Banding</keyword>
  <keyword>Endotoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

